Exicure, Inc. (XCUR): Price and Financial Metrics


Exicure, Inc. (XCUR): $1.41

0.04 (+2.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XCUR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

XCUR POWR Grades

  • Growth is the dimension where XCUR ranks best; there it ranks ahead of 95.49% of US stocks.
  • XCUR's strongest trending metric is Growth; it's been moving down over the last 81 days.
  • XCUR ranks lowest in Stability; there it ranks in the 1st percentile.

XCUR Stock Summary

  • EXICURE INC's market capitalization of $6,900,836 is ahead of merely 1.76% of US-listed equities.
  • With a year-over-year growth in debt of -71.52%, EXICURE INC's debt growth rate surpasses just 3.12% of about US stocks.
  • Revenue growth over the past 12 months for EXICURE INC comes in at -472.61%, a number that bests just 0.07% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to EXICURE INC, a group of peers worth examining would be INFI, SONN, IMV, PULM, and DARE.
  • Visit XCUR's SEC page to see the company's official filings. To visit the company's web site, go to www.exicuretx.com.

XCUR Valuation Summary

  • XCUR's price/sales ratio is 0.8; this is 60.98% lower than that of the median Healthcare stock.
  • Over the past 57 months, XCUR's price/sales ratio has gone down 11.8.

Below are key valuation metrics over time for XCUR.

Stock Date P/S P/B P/E EV/EBIT
XCUR 2023-01-20 0.8 -2.0 -0.2 0.0
XCUR 2023-01-19 0.7 -1.8 -0.2 0.1
XCUR 2023-01-18 0.8 -1.9 -0.2 0.0
XCUR 2023-01-17 0.7 -1.8 -0.2 0.1
XCUR 2023-01-13 0.7 -1.8 -0.2 0.1
XCUR 2023-01-12 0.7 -1.6 -0.2 0.1

XCUR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XCUR has a Quality Grade of C, ranking ahead of 38.19% of graded US stocks.
  • XCUR's asset turnover comes in at 0.039 -- ranking 338th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows XCUR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.039 1 -0.674
2021-03-31 0.085 1 -0.500
2020-12-31 0.161 1 -0.327
2020-09-30 0.157 1 -0.336
2020-06-30 0.152 1 -0.444
2020-03-31 0.133 1 -0.757

XCUR Price Target

For more insight on analysts targets of XCUR, see our XCUR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.00 Average Broker Recommendation 1.38 (Strong Buy)

XCUR Stock Price Chart Interactive Chart >

Price chart for XCUR

XCUR Price/Volume Stats

Current price $1.41 52-week high $10.16
Prev. close $1.37 52-week low $0.63
Day low $1.35 Volume 7,903
Day high $1.44 Avg. volume 76,095
50-day MA $1.17 Dividend yield N/A
200-day MA $2.17 Market Cap 7.00M

Exicure, Inc. (XCUR) Company Bio


Exicure, Inc. operates as a clinical stage bio-technology company. The Company develops a new class of immunomodulatory and gene regulating drugs against validated targets, as well as addresses diseases such as oncology, immunology, and dermatology. Exicure serves customers in the United States.


XCUR Latest News Stream


Event/Time News Detail
Loading, please wait...

XCUR Latest Social Stream


Loading social stream, please wait...

View Full XCUR Social Stream

Latest XCUR News From Around the Web

Below are the latest news stories about EXICURE INC that investors may wish to consider to help them evaluate XCUR as an investment opportunity.

Exicure Inc. (NASDAQ: XCUR): A Competitive Analysis And Growth Prospects

In the last trading session, 1.29 million shares of the Exicure Inc. (NASDAQ:XCUR) were traded, and its beta was 0.77. Most recently the company’s share price was $1.28, and it changed around -$0.18 or -12.33% from the last close, which brings the market valuation of the company to $7.21M. XCUR currently trades at a discount … Exicure Inc. (NASDAQ: XCUR): A Competitive Analysis And Growth Prospects Read More »

Marketing Sentinel | December 27, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tueday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning!

William White on InvestorPlace | December 20, 2022

Why Entrada Therapeutics Shares Are Trading Lower By 32%; Here Are 31 Stocks Moving Premarket

Gainers IceCure Medical Ltd (NASDAQ: ICCM ) shares rose 158% to $2.42 in pre-market trading after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery. Exicure, Inc. (NASDAQ: XCUR ) shares rose 46% to $1.08 in pre-market trading. Exicure 10% owner CBI USA, Inc. acquired a total of 3,400,000 shares at an average price of $1.60. Verona Pharma plc (NASDAQ: VRNA ) rose 39.3% to $18.80 in pre-market trading after the company reported positive results of its Phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. Otonomy, Inc (NASDAQ: OTIC ) rose 28.6% to $0.1475 in pre-market trading after the company issued ...

Benzinga | December 20, 2022

AbbVie, Ipsen Terminate Partnerships With Exicure As Bankruptcy Concern Looms

Exicure Inc (NASDAQ: XCUR ) announced the termination of its collaboration agreements with AbbVie Inc (NYSE: ABBV ) and Ipsen BioPharm Limited (OTC: IPSEY ). Through separate agreements with AbbVie and Ipsen, Exicure was collaboratively advancing specified discovery programs in hair loss disorders and rare neurodegenerative disorders, respectively. As a result of this termination, Exicure can develop medicines targeting hair loss disorders, Angelman syndrome independently, and Huntington''s … Full story available on Benzinga.com

Benzinga | December 14, 2022

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

Business Wire | December 14, 2022

Read More 'XCUR' Stories Here

XCUR Price Returns

1-mo 22.61%
3-mo 0.71%
6-mo -43.60%
1-year -76.36%
3-year -98.03%
5-year N/A
YTD 22.61%
2022 -81.03%
2021 -88.58%
2020 -38.11%
2019 -19.21%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7754 seconds.